Association for Molecular Pathology develops standardized biomarker report template for providers
Joint consensus recommendation includes organizational representation from AMP, ASCO and CAP
13 Oct 2025
The Association for Molecular Pathology (AMP) has announced the publication of new best practice recommendations for improving how complex molecular profiling information is presented to oncologists and other healthcare providers.
The manuscript, titled 'Developing Consensus for a More Provider-Friendly Next-Generation Sequencing Molecular Biomarker Report: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists', was published in The Journal of Molecular Diagnostics. The biomarker report template is also available.
While next-generation sequencing testing for solid tumors is increasingly available, its use has been limited due to widespread shortages of qualified clinical laboratory professionals and the complexities involved in data interpretation. Most clinical laboratories produce their own report formats, which can vary significantly in terms of length and organization of results and other content.
To address these issues, AMP’s Clinical Practice Committee convened a multidisciplinary panel of experts to create a simplified and consensus-driven biomarker report template that providers could review and utilize more effectively for patient care. The AMP Provider-Friendly Biomarker Report Working Group included representatives from AMP, the American Society of Clinical Oncology and the College of American Pathologists.
Alanna J. Church, M.D., chair of AMP’s 2025 Clinical Practice Committee, said, “Oncologists who receive our molecular biomarker reports typically need to assess the clinical impact of specific somatic mutations, determine whether any available therapies target those mutations and evaluate the strength of supporting evidence in order to provide the best care for their patient.”
“This new highly anticipated biomarker report template offers recommendations to help laboratories implement the presentation of complex molecular profiling data in a clear, yet guideline-concordant format specifically designed for oncologists and other healthcare providers,” she added.
The working group’s proposed report template was informed by the team’s clinical expertise and a review of 17 NGS biomarker reports for solid tumors from public, private and academic laboratories. The template also incorporates extensive community feedback from a public comment period.
The panel of experts assessed specific components, including overall report length, presence of a summary section and biomarker results table, use of color and formatting, therapeutic guidance, references to clinical practice guidelines, inclusion of clinical trial options, background information on biomarkers, assay and coverage details and clear explanations of variants of uncertain significance.
AMP President Jane S. Gibson, Ph.D., lead author of the paper, said, “This joint consensus recommendation is intended to support broader use of NGS testing and to help optimize patient care,” said Gibson. “AMP is committed to revisiting and refining the report template as advances in science, technology and clinical practice continue to evolve.”